Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution

American Journal of Pathology

Volumn 167, Issue 1, 2005, Pages 129-139

  Bernasconi, Pia ^a   Barberis, Massimo ^b   Baggi, Fulvio ^a   Passerini, Laura ^a   Cannone, Maria ^b   Arnoldi, Elisa ^a   Novellino, Lorenzo ^c   Cornelio, Ferdinando ^a   Mantegazza, Renato ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

^b IRCCS MULTIMEDICA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR; CYTOKERATIN; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5;

ADULT; ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL INFILTRATION; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; FEMALE; GERMINAL CENTER; HUMAN; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INNATE IMMUNITY; MALE; MYASTHENIA GRAVIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THYMOMA; THYMUS;

EID: 21244469489     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62960-4     Document Type: Article

References (38)

1. Vincent A: Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol 2002, 2:797-804
2. Drachman DB: Myasthenia gravis. N Engl J Med 1994, 330: 1797-1810
3. Sommer N, Harcourt GC, Willcox N, Beeson D, Newsom-Davis J: Acetylcholine receptor-reactive T lymphocytes from healthy subjects and myasthenia gravis patients. Neurology 1991, 41:1270-1276
4. Marx A, Wilisch A, Schultz A, Gattenlohner S, Nenninger R, Müller-Hermelink HK: Pathogenesis of myasthenia gravis. Virchows Arch 1997, 430:355-364
5. Gronseth GS, Barohn RJ: Practice parameter: thymectomy for autoimmune myasthenia gravis (an evidence-based review). Neurology 2000, 55:7-15
6. Mantegazza R, Baggi F, Bernasconi P, Antozzi C, Confalonieri P, Novellino L, Spinelli L, Ferrò MT, Beghi E, Cornelio F: Video-assisted thoracoscopic extended thymectomy and extended transsternal thymectomy (T-3b) in non-thymomatous myasthenia gravis patients: remission after 6 years of follow-up. J Neurol Sci 2003, 212:31-36
7. Shi F-D, Ljunggren HG, Sarvetnick N: Innate immunity and autoimmunity: from self-protection to self-destruction. Trends Immunol 2001, 22:97-101
8. Akira S, Takeda K, Kaisho T: Toll-like receptors: critical proteins inking innate and acquired immunity. Nat Immunol 2001, 2:675-680
9. Shi F-D, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG: Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 2000, 1:245-251
10. Reinhardt C, Melms A: Elevated frequencies of natural killer T lymphocytes in myasthenia gravis. Neurology 1939, 52:1485-1487
11. Bendelac A, Rivera MN, Park S-H, Roark JU: Mouse CD1-specific NK1 T cells: development, specificity and function. Annu Rev Immunol 1997, 15:535-562
12. + thymocytes. J Immunol 1991, 146:1113-1117
13. Eimoto T, Kusano T, Ando K, Kikuchi M, Shirakusa T, Kawanami S: Nonneoplastic and nonhyperplastic thymus in myasthenia gravis. An immunohistochemical study with double immunoenzymatic labeling of basement membrane and cellular components. Am J Clin Pathol 1990, 94:36-43
14. Müller-Hermelink HK, Marx A, Kirchner T: Thymus. Anderson's Pathology. Edited by Damianov I, Lindner J. St Louis, Mosby Year-Book, 1996, pp 1218-1243
15. Kirchner T, Schalke B, Melms A, von Kugelgen TV, Müller-Hermelink HK: Immunohistological patterns of non-neoplastic changes in the thymus in myasthenia gravis. Virchows Arch B Cell Pathol Incl Mol Pathol 1986, 52:237-257
16. Jaretzki III A, Barhon RJ, Ernstoff RM, Kaminski HJ, Keesey JC, Penn AS, Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America: Myasthenia gravis. Recommendations for clinical research standards. Neurology 2000, 55:16-23
17. Marx A, Müller-Hermelink HK: From basic immunobiology to the upcoming WHO-classification of tumors of the thymus. The Second Conference on Biological and Clinical Aspects of Thymic Epithelial Tumors and Related Recent Developments. Pathol Res Pract 1999, 195:515-533
18. Bernasconi P, Torchiana E, Confalonieri P, Brugnoni R, Barresi R, Mora M, Cornelio F, Morandi L, Mantegazza R: Expression of transforming growth factor-β1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J Clin Invest 1995, 96:1137-1144
19. Ellis PSJ, Whitehead R: Mitosis counting-a need for reappraisal. Hum Pathol 1981, 12:3-4
20. Elston CW, Ellis IO: Pathological factors in breast cancer. 1. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410
21. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M: MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999, 189:1777-1782
22. da Silva CJ, Soldau K, Christen U, Tobias PS, Ulevitch RJ: Lipopolysaccharide is in close proximity to each of the proteins in its membrane receptor complex: transfer from CD14 to TLR4 and MD-2. J Biol Chem 2001, 276:21129-21135
23. Akira S, Takeda K: Toll-like receptors signalling. Nat Rev Immunol 2004, 4:499-511
24. Klinman D: Does activation of the innate immune system contribute to the development of rheumatoid arthritis?. Arthritis Rheum 2003, 48:590-593
25. Seibl R, Birchler T, Loeliger S, Hossle JP, Gay RE, Saurenmann T, Michel BA, Seger RA, Gay S, Lauener RP: Expression and regulation of Toll-like receptor 2 in rheumatoid arthritis synovium. Am J Pathol 2003, 162:1221-1227
26. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, Marshak-Rothstein A: Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002, 416:603-607
27. Bsibsi M, Ravid R, Gveric D, van Noort JM: Broad expression of Toll-like receptors in the human central nervous system. J Neuropathol Exp Neurol 2002, 61:1013-1021
28. Takeda K, Kaisho T, Akira S: Toll-like receptors. Annu Rev Immunol 2003, 21:335-376
29. Muzio M, Polentarutti N, Bosisio D, Manoj Kumar PP, Mantovani A: Toll-like receptor family and signalling pathway. Biochem Soc Trans 2000, 28:563-566
30. Zarember KA, Godowski PJ: Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002, 168:554-561
31. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F: Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999, 274:10689-10692
32. Mocellin S, Rossi CR, Pilati P, Nitti D, Marincola FM: Quantitative real-time PCR: a powerful ally in cancer research. Trends Mol Med 2003, 9:189-195
33. Mantegazza R, Baggi F, Antozzi C, Confalonieri P, Morandi L, Bernasconi P, Andreetta F, Simoncini O, Campanella A, Beghi E, Cornelio F: Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann NY Acad Sci 2003, 998:413-423
34. Schalke BC, Mertens HG, Kirchner T, Wegener S, Müller-Hermelink HK: Long-term treatment with azathioprine abolishes thymic lymphoid follicular hyperplasia in myasthenia gravis. Lancet 1987, 2:682
35. Roxanis I, Micklem K, Willcox N: True epithelial hyperplasia in the thymus of early-onset myasthenia gravis patients: implications for immunopathogenesis. J Neuroimmunol 2001, 112:163-173
36. Shiono H, Roxanis I, Zhang W, Sims GP, Meager A, Jacobson LW, Liu JL, Matthews I, Wong YL, Bonifati M, Micklem K, Stott DI, Todd JA, Beeson D, Vincent A, Willcox N: Scenarios for autoimmunization of T and B cells in myasthenia gravis. Ann NY Acad Sci 2003, 998:237-256
37. Cohen-Kaminsky S, Delattre RM, Devergne O, Rouet P, Gimond D, Berrih-Aknin S, Galanaud P: Synergistic induction of interleukin-6 production and gene expression in human thymic epithelial cells by LPS and cytokines. Cell Immunol 1991, 138:79-93
38. Levinson AI, Zheng Y, Gaulton G, Moore J, Pletcher CH, Song D, Wheatley LM: A new model linking intrathymic acetylcholine receptor expression and the pathogenesis of myasthenia gravis. Ann NY Acad Sci 2003, 998:257-265